Cognate BioServices expands manufacturing in U.S., Europe Contract development and manufacturing organization Cognate BioServices plans to expand cell and gene therapy manufacturing capacity, laboratory space, warehousing capabilities, and to increase office support at its facilities in the U.S. and Europe.
Development 'cookbooks' could speed up gene therapy Great strides have been made in the development of gene editing tools in the past decade, but translating the technology into real therapies to treat patients has taken longer than expected. How to accelerate this process was the subject of a panel discussion on January 13 at the Biotech Showcase virtual event. Discuss
Lentigen to manufacture vector for Oncternal Oncternal Therapeutics announced an agreement with Lentigen Technology, a subsidiary of Miltenyi Biotec, to manufacture lentiviral vectors for Octernal's investigational receptor tyrosine kinase-like orphan receptor 1-targeting chimeric antigen receptor T-cell therapy program.
How is the pharma-AI partnership landscape changing? Artificial intelligence (AI) is taking on a growing role in drug discovery and development, with some 250 firms in a market space that's worth over $9 billion. And developers of AI are becoming attractive acquisition targets for contract research organizations, according to Ulrik Kristensen, PhD, research analyst and founder of Emersion Insights. Discuss